Five Prime Announces Fourth Quarter and Full Year 2015 Financial Results
10 mars 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10
26 févr. 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel...
Five Prime Therapeutics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
04 févr. 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and...
Five Prime Therapeutics Announces Key Executive Appointments
01 févr. 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
Kevin Baker, Ph.D., appointed as Senior Vice President of Development SciencesRobert Sikorski, M.D., Ph.D., promoted to Senior Vice President of Global Clinical Development SOUTH SAN FRANCISCO,...
Five Prime Therapeutics Announces Preliminary Data From the Dose Escalation Portion of the Phase 1 Trial of FPA144 at the ASCO GI Cancers Symposium
21 janv. 2016 15h00 HE
|
Five Prime Therapeutics, Inc.
Preliminary data on anti-tumor activity, including two partial responses in six gastric cancer patients whose tumors overexpress the FGFR2b proteinFPA144 was well tolerated and differentiated from...
Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis (PVNS)
13 janv. 2016 09h15 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
Five Prime Therapeutics Provides Update on FP-1039 Clinical Program
11 janv. 2016 04h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel...
Five Prime Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
06 janv. 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and...
Five Prime Therapeutics Appoints Prominent Immuno-Oncology Thought Leaders to Scientific Advisory Board
05 janv. 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel...
Five Prime Therapeutics Appoints Drug Development Leaders to Board of Directors
03 déc. 2015 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein...